Award
National Cancer Institute 5R44CA290913-03
Development of small molecule therapeutics targeting AR-V7 for prostate cancer
Recipient
National Cancer Institute
Award Amount
$888,779.00
Ceiling
$888,779.00
Awarded
May 27, 2026
Identifier
5R44CA290913-03
Award for developing small molecule therapeutics targeting AR-V7 to treat castration-resistant prostate cancer, including medicinal chemistry and efficacy evaluation, funded by the National Cancer Institute.
Description
This project aims to develop dual inhibitors of AR-full length (AR-fl) and AR-V7 to treat castration-resistant prostate cancer, with activities including medicinal chemistry, toxicity studies, efficacy evaluation, and manufacturing. The award is from the National Cancer Institute, with a focus on innovative therapeutics for prostate cancer.